Genomic and clinical predictors of lacosamide response in refractory epilepsies
| Autor: | Heavin, Sinéad B., McCormack, Mark, Wolking, Stefan, Slattery, Lisa, Walley, Nicole, Avbersek, Andreja, Novy, Jan, Sinha, Saurabh R., Radtke, Rod, Doherty, Colin, Auce, Pauls, Craig, John, Johnson, Michael R., Koeleman, Bobby P. C., Krause, Roland, Kunz, Wolfram S., Marson, Anthony G., O'Brien, Terence J., Sander, Josemir W., Sills, Graeme J., Stefansson, Hreinn, Striano, Pasquale, Zara, Federico, EPIGEN Consortium, EpiPGX Consortium, Depondt, Chantal, Sisodiya, Sanjay, Goldstein, David, Lerche, Holger, Cavalleri, Gianpiero L., Delanty, Norman |
|---|---|
| Přispěvatelé: | EPIGEN Consortium, EpiPGX Consortium, Wellcome Trust, Imperial College Healthcare NHS Trust- BRC Funding, Commission of the European Communities, Medical Research Council (MRC) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Candidate gene lacosamide Lacosamide Neurology [D14] [Human health sciences] Clinical Neurology Genome-wide association study lcsh:RC346-429 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Medicine GWAS EpiPGX Consortium Exome lcsh:Neurology. Diseases of the nervous system 030304 developmental biology Genetic association pharmacogenomics 0303 health sciences Neurologie [D14] [Sciences de la santé humaine] business.industry EPIGEN Consortium Généralités pharmacoresistance refractory 3. Good health Neurology Pharmacogenomics Cohort Full‐length Original Research Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Epilepsia open, vol. 4, no. 4, pp. 563-571 Epilepsia Open, 0(0). (2019). Epilepsia Open, Vol 4, Iss 4, Pp 563-571 (2019) Epilepsia Open Epilepsia Open, 4(4), 563. Wiley-Blackwell Publishing Ltd |
| ISSN: | 2470-9239 |
| Popis: | Objective: Clinical and genetic predictors of response to antiepileptic drugs (AEDs) are largely unknown. We examined predictors of lacosamide response in a real-world clinical setting. Methods: We tested the association of clinical predictors with treatment response using regression modeling in a cohort of people with refractory epilepsy. Genetic assessment for lacosamide response was conducted via genome-wide association studies and exome studies, comprising 281 candidate genes. Results: Most patients (479/483) were treated with LCM in addition to other AEDs. Our results corroborate previous findings that patients with refractory genetic generalized epilepsy (GGE) may respond to treatment with LCM. No clear clinical predictors were identified. We then compared 73 lacosamide responders, defined as those experiencing greater than 75% seizure reduction or seizure freedom, to 495 nonresponders ( SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text